David O'Malley

23PUBLICATIONS
232CO-AUTHORS
Cancer cell biologyMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|May 22, 2026
Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer.

|Dec 12, 2025
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Brian M Slomovitz, S John Weroha, Wei Deng

|Dec 11, 2025
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Robert L Hollis, Austin Miller, Heather A Lankes

|Jul 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian

|Jan 09, 2025
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial.

Jyoti Mayadev, Dmitriy Zamarin, Wei Deng

|Dec 19, 2024
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.

Daniela E Matei, Danielle M Enserro, Marcus E Randall

Pageof 4

Frequent Collaborators

9 joint publications

Bradley J Monk

6 joint publications

Susana N Banerjee

6 joint publications

Robert L Coleman

5 joint publications

Kathleen N Moore